Who
Jane Wasman
Director
Company insider
Files Form 4 as: Director, Rigel Pharmaceuticals; Director, SELLAS Life Sciences Group; Director, Athersys, Inc / New; President, Intl and GC, Acorda Therapeutics.
In numbers
- Trades disclosed
- 312
- Buys
- 1
- Sells
- 42
- Bought
- $34K
- Sold
- $8.4M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 15 Feb 2006
- Last trade
- 15 May 2026
- Last filed
- 19 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 May 2026filed 19 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Bought | $34K20,000 at $1.69 | filing |
| 23 May 2025filed 28 May 2025 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 23 May 2025filed 28 May 2025 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 10 Jan 2025filed 14 Jan 2025 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 10 Jan 2025filed 14 Jan 2025 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 25 May 2024filed 29 May 2024 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 25 May 2024filed 29 May 2024 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 22 Jan 2024filed 25 Jan 2024 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 22 Jan 2024filed 25 Jan 2024 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 26 May 2023filed 12 Jul 2023 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 26 May 2023filed 12 Jul 2023 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 2 Feb 2023filed 3 Feb 2023 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,500 at $0.00 | filing |
| 2 Feb 2023filed 3 Feb 2023 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 9 Jan 2023filed 11 Jan 2023 | Athersys, Inc / New | SEC FORM 4 Code A | —22,321 at $0.00 | filing |
| 16 Sep 2022filed 20 Sep 2022 | Athersys, Inc / Newoption or derivative | SEC FORM 4 Code A | —32,042 at $0.00 | filing |
| 16 Sep 2022filed 20 Sep 2022 | Athersys, Inc / New | SEC FORM 4 Code A | —12,820 at $0.00 | filing |
News
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down – Here's WhySLS · dailypolitical.com · 20 Oct 2026SELLAS Life Sciences Group (NASDAQ:SLS) Stock Falls 11.2% – Should You Sell?SLS · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Jane Wasman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.